SWELL1 channel-mediated D-2HG export promotes immune evasion and metabolic fitness in IDH-mutant gliomas.
Cheng Henry Yi HY, Ma Lifei L, Chen Jianan J, Huang Jiale J et al.
Isocitrate dehydrogenase (IDH) is the most frequently mutated metabolic enzyme in human cancers. Mutant IDH produces D-2-hydroxyglutarate (D-2HG), which promotes tumorigenesis through epigenetic alterations. Beyond cell-autonomous effects, tumor-derived D-2HG acts as a potent immunosuppressant that establishes an immune-cold tumor microenvironment (TME). However, the mechanism by which D-2HG is released from tumors remains largely unknown. Here, we identify the SWELL1 (LRRC8A)/LRRC8C-containing volume-regulated anion channel (VRAC) as a principal pathway for D-2HG efflux from IDH-mutant cells. Deletion of SWELL1, the essential VRAC subunit, markedly reduces D-2HG release and reverses associated immunosuppression in an orthotopic mouse model of IDH-mutant glioma. Strikingly, VRAC loss causes intracellular D-2HG accumulation, which paradoxically limits glioma proliferation by driving epigenetic remodeling and mitochondrial metabolic stress. Pharmacological VRAC inhibition with dicumarol suppresses IDH-mutant glioma growth, enhances intratumoral T cell activation, synergizes with immune checkpoint blockade, and prolongs survival in tumor-bearing mice. In human IDH-mutant lower-grade gliomas, elevated LRRC8C expression correlates inversely with DNA hypermethylation and positively with an immunosuppressive TME, and is associated with poor survival. Together, these findings establish VRAC-mediated D-2HG export as a previously unrecognized D-2HG clearance pathway that promotes both immune evasion and tumor cell fitness, uncovering new therapeutic opportunities beyond direct inhibition of D-2HG synthesis.